Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical experience, including leadership roles at BioMarin Pharmaceutical. His expertise will help Neion expand capabilities for producing complex therapeutic proteins more efficiently and cost-effectively. This move aims to advance Neion's goal of revolutionizing biologics manufacturing by leveraging the unique biology of chickens for scalable, low-cost production.
Neion Bio's leadership update provides context for readers following health sector developments. For readers following health sector stocks, here is Pluang's market snapshot as of Nov 04, 2026 23:12 WIB: Among 150 priced US health-sector stocks tradable on Pluang, 106 rose and 43 fell today. Notable movers include TLRY (Tilray Brands Inc) at USD 2.95 with a 1-day change of +11.32% and Pluang order activity of 96% Sell / 4% Buy, NUWE (Nuwellis Inc) at USD 5.31 with a 1-day change of -10.15% and 100% Sell activity, and MRNA (Moderna, Inc.) at USD 250.38 with a 1-day change of +9.60% and 76% Sell / 24% Buy activity, with typical hold times ranging from 31 to 58 days on Pluang.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
